Phase I Dose Escalation Multicenter Trial of Pracinostat Alone and in Combination with Azacitidine in Patients with Advanced Hematologic Malignancies

BACKGROUND: Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines. Pracinostat has modest clinical activity in advanced solid tumors. Given the higher preclinical sensitivity of hematologic malignancies to pracin...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Abaza, Yasmin, Kadia, Tapan, Jabbour, Elias, Konopleva, Marina, Borthakur, Gautam, Ferrajoli, Alessandra, Estrov, Zeev, Wierda, William, Alfonso, Ana, Chong, Toh Han, Chuah, Charles, Koh, Liang-Piu, Goh, Boon-Cher, Chang, Julie E., Durkes, Daniel, Foudray, Maria Cielo, Kantarjian, Hagop, Dong, Xiao Qin, Garcia-Manero, Guillermo
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5901648/
https://ncbi.nlm.nih.gov/pubmed/28841236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30949
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki